Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02390297 · ClinicalTrials.gov registry record

Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients

A clinical trial of HIV-1-infection and Receipt of Cal-1 Modified Hematopoietic Cellular Products, sponsored by Calimmune.

Active
Registry status
11
Enrollment target
2
Study locations

NCT02390297 is a study of HIV-1-infection and Receipt of Cal-1 Modified Hematopoietic Cellular Products that is active but no longer recruiting, run by Calimmune. The registered enrollment target is 11 participants, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02390297, a study of HIV-1-infection and Receipt of Cal-1 Modified Hematopoietic Cellular Products, is active but no longer recruiting, sponsored by Calimmune.

ACTIVE NOT RECRUITING
Registry status
11 participants
Enrollment target
2
Study locations

Study Summary

Long term safety follow-up of Cal-1 recipients

Interventions

  • GENETIC Blood tests

Study Locations (2)

California

  • UCLA CARE Center - Los Angeles
  • Quest Clinical Research - San Francisco

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2015-04
Est. Completion 2031-10

Sponsor

Calimmune

2 total trials

What the Registry Record Tells You About NCT02390297

The ClinicalTrials.gov registry entry for NCT02390297 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (97% lower). The listed sponsor is Calimmune, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with HIV-1-infection appearing as the primary indexed condition, and to 1 intervention - of which Blood tests is the first listed.

NCT02390297 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT02390297 about?

NCT02390297 is a clinical study titled "Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients". Long term safety follow-up of Cal-1 recipients

What is the current status of trial NCT02390297?

This trial is currently active not recruiting. The enrollment target is 11 participants. The study started on 2015-04. Estimated completion is 2031-10.

What conditions does trial NCT02390297 study?

This clinical trial studies the following conditions: HIV-1-infection, Receipt of Cal-1 Modified Hematopoietic Cellular Products.

What interventions are being tested in trial NCT02390297?

The interventions under investigation include: Blood tests (GENETIC).

Who is sponsoring clinical trial NCT02390297?

This trial is sponsored by Calimmune, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02390297 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV-1-infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.